ArticleMedicine2026
Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum biomarkers that reflect both tumor burden and host response may provide valuable prognostic information in metastatic colorectal cancer (mCRC). Carbohydrate antigen 19-9 (CA19-9) and albumin levels have been associated with disease outcomes; however, the prognostic value of their ratio has not been evaluated in de novo mCRC. This study aimed to investigate the prognostic significance of the pretreatment CA19-9/albumin ratio in patients with de novo mCRC who were treated with standard combination chemotherapy and biologic agents. A total of 178 patients diagnosed with de novo mCRC between 2013 and 2024 were retrospectively analyzed. The CA19-9/albumin ratio was calculated by dividing serum CA19-9 (U/mL) by albumin (g/dL), and the optimal cutoff value was determined using receiver operating characteristic curve analysis. Patients were classified into low- and high-ratio groups. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and independent prognostic factors were identified through multivariate Cox regression analyses. The optimal cutoff value for the CA19-9/albumin ratio was 5.81. Patients with a high-ratio had significantly shorter PFS (median 9.6 vs 16.1 months, P = .002) and OS (median 23.3 vs 32.6 months, P = .005) compared with those with a low-ratio. In multivariate analyses, a high CA19-9/albumin ratio independently predicted shorter PFS (hazard ratio 0.60, 95% confidence interval [CI] 0.41-0.89, P = .011) and OS (hazard ratio 0.66, 95% confidence interval 0.44-0.99, P = .042). The CA19-9/albumin ratio is a simple, inexpensive, and easily obtainable serum biomarker that independently predicts survival in patients with de novo mCRC. This composite biomarker may better reflect the combined effects of tumor burden and host status, providing additional prognostic value beyond conventional markers. Prospective multicenter studies are warranted for further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.